Celldex Therapeutics (CLDX) executive compensation, 2026 proxy

Anthony S. Marucci, President and Chief Executive Officer, was paid $5.4M in 2025, down 42% from $9.2M the year before. The CEO-to-median-employee pay ratio was 23:1, on median employee pay of $235,733.

Filed
April 29, 2026
Annual meeting
June 25, 2026
Pay year
2025
Named executives
5
CEO total pay
$5.4M-42% vs prior year
CEO to median employee
23:1median $235,733
Prior say-on-pay support
99%of votes cast
CEO Total Compensation
$5,366,7092025 Summary Compensation Table Total
Prior Year CEO Total
$9,229,1652024 Summary Compensation Table Total
CEO to Median Employee Pay Ratio
23:1Based on 2025 CEO pay
Median Employee Pay
$235,733Annual total compensation
Say-on-Pay Support
99%Approval at 2025 annual meeting

How Marucci was paid

$5.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary15%Bonus10%Option awards75%All other compensation0%

Named executive officers

ExecutiveTotal
Anthony S. MarucciPresident and Chief Executive Officer$5,366,709
Tibor Keler, Ph.D.Executive Vice President and Chief Scientific Officer$2,115,717
Elizabeth CrowleySenior Vice President, Chief Product Development Officer$1,885,209
Margo Heath-Chiozzi, M.D.Senior Vice President, Regulatory Affairs$1,820,359
Sam MartinSenior Vice President and Chief Financial Officer$1,827,112

What changed and why

  • $5.4MChief Executive Officer Anthony S. Marucci received total compensation of $5,366,709 in fiscal 2025.
  • $9.2MCEO total compensation decreased from $9,229,165 in the prior fiscal year.
  • 100%The Compensation Committee determined a corporate goal payout factor of 100% of target.
  • 4.0%Base salaries for Named Executive Officers were increased by 4.0% to 6.0% in June 2025.
  • 1.4%A subsequent market adjustment increased base salaries by 1.4% to 4.6% in December 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.